Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.

ABSTRACT:

Background

Sequential inhibition of the vascular endothelial growth factor (VEGF) pathway with sorafenib could be useful for patients with metastatic renal cell carcinoma (RCC). Our aim was to determine the activity and tolerability of sorafenib as a second-line therapy in advanced RCC initially treated with a different VEGF-tyrosine kinase inhibitor (TKI).

Methods

A prospective observational cohort in Mexico (2012-2019). We included 132 subjects with metastatic RCC and who had progression despite treatment with sunitinib. The primary end-point was time to disease progression as evaluated every 12-16 weeks.

Results

The mean age of the cohort was 59 years (interquartile range [IQR] 50-72), 96 (73%) were men, and 48 (36%) had a favorable prognosis according to the IMDC

SUBMITTER: Martin-Aguilar AE 

PROVIDER: S-EPMC7786959 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature